| Primary |
| Cystinuria |
28.6% |
| Nephrolithiasis |
28.6% |
| Calculus Urinary |
14.3% |
| Muscle Spasms |
14.3% |
| Renal Stone Removal |
14.3% |
|
| Drug Dispensing Error |
20.0% |
| Bronchiectasis |
10.0% |
| Intercepted Drug Dispensing Error |
10.0% |
| Muscle Spasms |
10.0% |
| Nephrolithiasis |
10.0% |
| Product Substitution Issue |
10.0% |
| Stag Horn Calculus |
10.0% |
| Unevaluable Event |
10.0% |
| Wrong Drug Administered |
10.0% |
|
| Secondary |
| Bipolar Disorder |
12.8% |
| Nephrolithiasis |
11.6% |
| Hypertension |
10.5% |
| Product Used For Unknown Indication |
8.1% |
| Contraception |
7.0% |
| Cystinosis |
7.0% |
| Post-traumatic Stress Disorder |
5.8% |
| Depression |
4.7% |
| Generalised Anxiety Disorder |
4.7% |
| Gout |
3.5% |
| Mood Swings |
3.5% |
| Non-hodgkin's Lymphoma |
3.5% |
| Affective Disorder |
2.3% |
| Arthritis |
2.3% |
| Epilepsy |
2.3% |
| Migraine Prophylaxis |
2.3% |
| Pain |
2.3% |
| Renal Tubular Acidosis |
2.3% |
| Schizophrenia |
2.3% |
| Affect Lability |
1.2% |
|
| Nephrolithiasis |
14.3% |
| Dizziness |
9.5% |
| Wrong Drug Administered |
9.5% |
| Abdominal Discomfort |
4.8% |
| Calculus Urinary |
4.8% |
| Chills |
4.8% |
| Eye Disorder |
4.8% |
| Headache |
4.8% |
| Hypercalciuria |
4.8% |
| Interstitial Granulomatous Dermatitis |
4.8% |
| Medication Error |
4.8% |
| Odynophagia |
4.8% |
| Pyrexia |
4.8% |
| Renal Impairment |
4.8% |
| Somnolence |
4.8% |
| Weight Increased |
4.8% |
| Wound |
4.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
26.3% |
| Drug Use For Unknown Indication |
16.0% |
| Prophylaxis |
8.3% |
| Crohn's Disease |
7.9% |
| Hypertension |
5.4% |
| Nephrolithiasis |
4.5% |
| Pain |
4.3% |
| Prostate Cancer |
3.1% |
| Gastrooesophageal Reflux Disease |
2.8% |
| Vitamin Supplementation |
2.4% |
| Diabetes Mellitus |
2.2% |
| Depression |
2.1% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Cardiac Disorder |
1.9% |
| Constipation |
1.9% |
| Osteopenia |
1.9% |
| Rheumatoid Arthritis |
1.9% |
| Mineral Supplementation |
1.7% |
| Supplementation Therapy |
1.7% |
| Osteoporosis |
1.6% |
|
| Vomiting |
13.4% |
| Squamous Cell Carcinoma |
9.4% |
| Diarrhoea |
6.0% |
| Drug Ineffective |
6.0% |
| Nephrolithiasis |
6.0% |
| Weight Decreased |
6.0% |
| Tooth Fracture |
5.4% |
| Paraesthesia |
4.7% |
| Bladder Cancer Recurrent |
4.0% |
| Injection Site Pain |
4.0% |
| Somnolence |
4.0% |
| Visual Disturbance |
4.0% |
| White Blood Cell Count Decreased |
4.0% |
| Death |
3.4% |
| Off Label Use |
3.4% |
| Pruritus |
3.4% |
| Pulmonary Embolism |
3.4% |
| Urticaria |
3.4% |
| Vision Blurred |
3.4% |
| Dehydration |
2.7% |
|
| Interacting |
| Nephrolithiasis |
26.7% |
| Back Pain |
13.3% |
| Blood Pressure |
13.3% |
| Erectile Dysfunction |
13.3% |
| Arterial Occlusive Disease |
6.7% |
| Arterial Spasm |
6.7% |
| Blood Cholesterol Increased |
6.7% |
| Blood Triglycerides Increased |
6.7% |
| Hypertension |
6.7% |
|
| Nephrolithiasis |
33.3% |
| Sluggishness |
33.3% |
| Urticaria |
33.3% |
|
